Replies to post #2915 on Biomoda Inc. (fka BMODQ)

[The Rainmaker]

Dug out the Cypath Phase I testing showed 100% accuracy quote....

CLINICAL STUDY UPDATE

On March 5, 2009, we received approval from an independent Institutional Review Board (IRB) to begin Phase II clinical trials of our cytology-based screening technology for early detection of cancer. Biomoda’s proprietary technology had previously shown 100 percent sensitivity and 100 percent specificity during internal testing on a small sample of patients.

[The Rainmaker]

Lung Check ran a larger sample and that test used 59 total samples, 52 plus 7 and got 96.2% accuracy.

LungCheck conducted a study for Biomoda. For this study, LungCheck used 52 samples from patients with dysplasia, carcinoma in situ (CIS) and lung cancer (adenocarcinoma, squamous cell carcinoma, small cell carcinoma) and seven samples from patients with metaplasia as "controls." The sensitivity, a measurement of accuracy, for this study was calculated at 96.2 percent.


Phase II pilot study used 130 samples plus 21 from second cohort. This is the first test results to be released via FDA so this next one is the real validator and confidence builder for the markets.